David Meriwether, PhD

Key investigator

  • David Meriwether, PhD

Awards

  • K01 grant from NIH-NIDDK for dysregulation of inflammation resolution as therapeutic target for IBD (2023)
    • Under the KO1 grant, Dr. Meriwether will first investigate the physiological mechanism by which inflammation-resolving macrophages stimulate human intestinal epithelial repair from inflammatory injury. Second, he will determine the molecular mechanism by which IBD-dependent oxidized lipids can dysregulate macrophage efferocytosis and macrophage-dependent intestinal epithelial repair. Finally, he will investigate the potential of APOA1 mimetic peptides to rescue macrophage inflammation resolution potential by stimulating the clearance and sequestration of mucosal oxidized lipids.

About Dr. Meriwether

Dr. Meriwether received his PhD in molecular and medical pharmacology from UCLA in 2018. After three years of post-doctoral training in the laboratory of Drs. Srinu Reddy and Alan Fogelman, he joined the UCLA Division of Digestive Diseases in 2021. Dr. Meriwether is an intestinal epithelial and inflammation biologist who investigates the pathogenesis and pathophysiology of inflammatory bowel disease. His current work focuses in part on IBD-dependent dysregulation of inflammation resolution and resolution-dependent intestinal epithelial repair.